Dyne Therapeutics (DYN)
(Delayed Data from NSDQ)
$25.44 USD
+0.89 (3.63%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $25.46 +0.02 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DYN 25.44 +0.89(3.63%)
Will DYN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DYN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DYN
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
DYN: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Dyne Therapeutics, Inc. (DYN) Rating Upgrade to Strong Buy
Does Dyne Therapeutics, Inc. (DYN) Have the Potential to Rally 84% as Wall Street Analysts Expect?
Here's Why Dyne Therapeutics, Inc. (DYN) Is a Great 'Buy the Bottom' Stock Now
Other News for DYN
Edgewise gets EU orphan drug status for muscular dystrophy drug
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
Analysts Are Bullish on Top Healthcare Stocks: Dyne Therapeutics (DYN), Addus Homecare (ADUS)
United Airlines, Dyne Therapeutics fall; Lucid Group, Century Aluminum rise, Monday, 3/25/2024